GLUCAGON / GLP-1 DUAL RECEPTOR AGONIST

Survodutide

A late-stage glucagon/GLP-1 dual agonist with Phase 3 obesity evidence and a dedicated mechanistic study comparing energy use and fat metabolism with semaglutide.

Evidence Maturity · M4 — Advanced clinical Investigational — Phase 3
Evidence reviewed: September 19, 2026Source-labeled

Signal summary

Survodutide is a dual glucagon/GLP-1 receptor agonist being developed for obesity and metabolic liver disease. Its glucagon component makes energy expenditure and fat metabolism particularly relevant to the RecompSignal lens.

Signal interpretation: Survodutide has matured beyond an early pipeline story: Phase 3 obesity trials are completed or completing, and a separate mechanistic study directly compares metabolic effects with semaglutide. Composition-specific conclusions should still wait for detailed outcome data.

Study details

Doses studied — not a dosing recommendation. Regimens belong to the named study, formulation and population.

SYNCHRONIZE-1 phase 3 trial

Population
725 randomized adults with obesity/overweight and complications, excluding diabetes.
Doses and administration studied
Subcutaneous treatment adjusted up to 3.6 or 6.0 mg once weekly versus placebo.
Duration
76 weeks
Reported finding / status
Treatment-regimen mean weight changes: -12.2% and -13.0%, versus -5.4% placebo.
Interpretation and limitations
Gastrointestinal symptoms were frequent. Weight results do not establish lean-mass or functional benefit; completed CVOT follow-up is not proof of cardiovascular benefit.

Source tier B · Read the original study or record

Outcome Evidence Strength

Weight change3/5
Fat-mass change0/5
Lean-mass change0/5
Strength / function benefit0/5

Weight: published phase 3 RCT. The cited report does not establish direct fat-selectivity, lean preservation or function benefits.

Editorial evidence ratings for the cited outcomes, not effect size or treatment recommendations. A lean-mass score may describe loss. 0 means not established in the reviewed evidence, not proof of no effect. Read the rubric.

What is actually established?

  • SYNCHRONIZE-1, the Phase 3 obesity trial in adults without diabetes, is completed and has a 2026 New England Journal of Medicine publication listed on ClinicalTrials.gov.
  • The large Phase 3 cardiovascular outcomes trial enrolled more than 5,500 participants and completed follow-up in 2026.
  • A dedicated study is comparing survodutide with semaglutide on energy use and fat metabolism.

What is not established?

  • Survodutide remains investigational.
  • Metabolic mechanism does not automatically translate into superior body-composition outcomes.
  • Detailed lean-mass and function comparisons remain less mature than weight-loss evidence.

Evidence sources

A = regulatory/official • B = peer-reviewed randomized/meta-analysis • C = peer-reviewed review/observational • D = registered trial • E = sponsor-reported • F = preclinical

Source tier B/D — Phase 3 publication/registry
SYNCHRONIZE-1 Phase 3 obesity study
Source tier D — Mechanistic trial
Survodutide vs semaglutide energy-use/fat-metabolism study
Source tier D — CV outcomes trial
SYNCHRONIZE-CVOT

Last evidence review: September 19, 2026.

Educational use only. This page summarizes research evidence and regulatory status. Study doses describe research, not prescribing instructions. This page does not provide personalized dosing, self-use protocols, sourcing, or a recommendation to use this therapy.